Nutri-GenX LC Pioneered the Field of Epigenetic Nutrition and Wellness
Epigenetics is the only hope that the human race has for survival today if we do not curb the epidemic rise in Diabetes, Obesity, Cancer and Immune diseases. At Nutri-GenX we have centered our research and development around Anti-aging, Anti-stress and what we believe to be the Environmental toxins that have set us upon this deadly course. We understand genetics, polymorphisms and environmental factors that make choosing the right nutritional supplement critical in today's stressful, toxic environment. 80% of the Worlds adult population today is clinically deficient in one or more critical nutrients that will have a negative impact on the quality of their lives as they age.
Epigenetics "our past + our genes" carry the answers so this dismal outcome doesn’t have to happen to you or your loved ones. because you now have a choice to improve your health, your children and your grandchildren. Supplementation is painless and by far the cheapest health insurance in the world at only pennies a day. Why risk the misery and expense of a preventable long term Illness or nutritional disease like obesity, diabetes or cancer. These are just a few of the preventable diseases that can rob you of your health, vitality and quality of life as you age.
We Started a Revolution With Just One Shot
ProX NutriShot
Energize Your Life
The following article is an example of what we are talking about in the field of epigenetics today. Vitamin D deficiency leads to a higher incidence of contracting Epstein-Barr virus if exposed and that is linked to contracting MS later in life. That's all from a deficiency in Vitamin D.
Low Vitamin D, Epstein-Barr, Linked to Later MS
August 24, 2012 — Low levels of vitamin D and exposure to the
Epstein-Barr virus (EBV) have been linked to the development of
multiple sclerosis (MS),
new research shows.
"Changes [in both] vitamin D levels and EBV immunoreactivity even 2
to 3 years prior to the first clinical disease manifestation appear to
be associated with clinical breakthrough. So we are looking at 2
factors together several years before the first symptoms and signs of
MS," study author Andrew Chan, MD, from St. Josef-Hospital,
Ruhr-University, in Bochum, Germany, told
Medscape Medical News.
|
Dr. Andrew Chan
|
However, investigators could not determine whether one of these risk factors is more important in the development of MS.
"I believe it is safe to say that both factors are associated with
clinical disease breakthrough, possibly within a relatively restricted
interval," said Dr. Chan. Whether they are independent risk factors
that are amenable to intervention remains to be seen, he added.
The study was published online August 11 in
Journal of Neurology, Neurosurgery & Psychiatry.
Low Vitamin D
The analysis included 56 blood samples donated by 25 patients in
Germany (21 female; mean age, 31.5 years at time of donation; 33.4 years
when they developed MS).
Researchers obtained serum samples from 18 of the 25 participants
after an MS diagnosis was established, and collected 39 serum samples
from 25 age- and gender-matched healthy blood donors.
From these samples, researchers investigated both 25-hydroxyvitamin D
(25-OH-D) serum levels and immunoglobulin C (IgC) response against the
EBV nuclear antigen-1 (EBNA1).
EBNA1 is important for establishing and maintaining the altered state
of cells following infection with EBV, according to Masaaki Niino, MD,
PhD, director, Department of Clinical Research, Hokkaido Medical
Center, Sapporo, Japan, who contributed a
related editorial. The risk for MS increases more than 7-fold with increasing titers of anti–EBNA1 IgC antibodies, he said.
Cross-sectional analyses revealed a gradual decrease in 25-OH-D
levels during the pre–clinically isolated syndrome (CIS) phase. This
change was particularly evident during the 24 months before CIS
(median, 47.8 mmol/L vs 81.6 mmol/L for healthy controls;
P = .004).
Not an Isolated Finding
After an MS diagnosis was established, levels were strongly reduced — median, 24.5 mmol/L (
P < .0001) — compared with those of pre-CIS sera (57.1 mmol/L) or healthy controls.
In contrast, IgC response against EBNA1 was increased during the
pre-CIS phase compared with that of healthy matched blood donors. The
most pronounced alterations were seen in the 36 months before
clinical manifestation (median, 185.9 IU/mL vs 63.7 IU/mL for healthy
controls;
P = .002).
Reverse causality — long-standing disease processes causing changes
in 25-OH-D and EBNA1 status — cannot be excluded, according to the
authors.
Although the current study did not detect any direct relationship
between 25-OH-D levels and EBNA1 immunoreactivity, some previous
experimental data did suggest that the 2 factors may work
synergistically, said Dr. Chan.
"For example, vitamin D may influence the immune reaction to EBV."
Dr. Chan hypothesized that the influence of vitamin D on EBV
immunoreactivity or on other adaptive immune responses could be
especially important during the interval highlighted in the study.
Larger studies are needed to address this issue, he said.
The study included only white patients living in Germany, but its
results are compatible with those from other studies from different
geographic regions, said Dr. Chan. "I would guess that this is not
an isolated finding."
Hypothesis-Generating Results
Dr. Chan cited another very large study — conducted with samples from
US military staff — that linked lower vitamin D levels with higher risk
of developing MS later in life.
"However, in their study, vitamin D levels before the age of 20
[were] important, whereas we saw profound changes a couple of years
prior to disease onset," said Dr. Chan.
"Whereas the cohorts can't be directly compared because of selection
bias, size, etc, I believe the datasets complement one another, and that
our results are hypothesis-generating," he added.
The current study combined results for men (only 4) and for women, so
it is possible that the results may be gender-specific. However, Dr.
Chan and colleagues addressed the issue of sex differences by using
gender/age-matched controls.
The study used samples that dated back several years but, according
to Dr. Chan, it is unlikely that it would be possible to track the
association back any farther.
"While we were able to obtain samples up to 7 years prior to disease
manifestations, many blood donor centers do not keep samples for very
long intervals for logistical reasons. Most of the centers we
contacted kept the samples for about 5 years. Therefore, it is very
difficult to track down even earlier time points."
Among the drawbacks of the study were its limited sample size,
possible recall bias, and inability to dissect determinants of
individual vitamin D levels, including sunlight exposure and diet.
Need for Research in Diverse Populations
In his commentary, Dr. Niino said that the study helps answer the
question of whether long-term low vitamin D levels and indication of
remote EBV infection are associated with risk factors for developing
MS.
"These findings suggest that the 2 major risk factors of low vitamin D
level and remote EBV infection are important, especially during the few
years prior to clinical manifestation."
Dr. Niino also noted that vitamin D levels — or at least 25-OH-D
levels — are known to differ between races and ethnicities, perhaps
because of skin color. Although it is possible that study results
would hold true for other ethnicities, to date, few related data have
been collected, he said. "We need similar studies with other
ethnicities, including Japanese."
Dr. Niino agreed with the authors that although the study did not
uncover a direct relationship between the 2 MS risk factors
investigated, "further prospective studies are needed to investigate
potential interactions of vitamin D level and remote EBV infection."
Dr. Chan has disclosed that he
received personal compensation as a speaker or consultant for Bayer
Schering, Biogen Idec, Merck Serono, Novartis, Sanofi-Aventis,
and Teva Neuroscience, as well as research support from the German
Ministry for Education and Research (BMBF, German Competence Network
Multiple Sclerosis [KKNMS], CONTROL MS, 01GI0914), Bayer Schering,
Biogen Idec, Merck Serono, and Novartis. Dr. Niino has disclosed that he
receives research support from Grants-in-Aid for Scientific
Research from the Ministry of Health, Labor, and Welfare of Japan, and
from the National Hospital Organization of Japan; that he serves
on a scientific advisory board for Biogen Idec; and that he has
received speaker honoraria from Biogen Idec, Bayer Schering
Pharma, Asahi Kasei Kuraray Medical Co Ltd, and Novartis Pharma.
J Neurol Neurosurg Psychiatry. Published online August 11, 2012.
Abstract
J Neurol Neurosurg Psychiatry. Published online August 20, 2012.
Editorial extract
